Gastroduodenal safety and tolerability of Lumiracoxib in patients with rheumatoid arthritis

被引：0
|
作者：
Kivitz, AJ
Nayiager, S
Schimansky, T
Gimona, A
Thurston, HJ
Hawkey, CJ
机构：
[1] Altoona Ctr Clin Res, Duncansville, TX USA
[2] St Augustines Hosp, Med Ctr 2, Berea, South Africa
[3] Novartis Pharma AG, CR & D, Basel, Switzerland
[4] Univ Hosp, Div Gastroenterol, Nottingham, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [1] Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis
    Geusens, P
    Alten, R
    Rovensky, J
    Sloan, VS
    Krammer, G
    Kralidis, G
    Richardson, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (11) : 1033 - 1041
  • [2] Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis
    Hawkey, CJ
    Gitton, X
    Hoexter, G
    Richard, D
    Weinstein, WM
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (01) : 57 - 66
  • [3] Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis
    Hawkey, CC
    Svoboda, P
    Fiedorowicz-Fabrycy, IF
    Nasonov, EL
    Pikhlak, EG
    Cousin, M
    Gitton, X
    Hoexter, G
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (09) : 1804 - 1810
  • [4] Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: Results of a randomized double-blind study
    Geusen, P
    Alten, R
    Rovensky, J
    Sloan, V
    Krammer, G
    Kralidis, G
    Richardson, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S242 - S242
  • [5] Lumiracoxib similar gastroduodenal tolerability to celecoxib
    Reactions Weekly, 2004, 1023 (1) : 5 - 5
  • [6] Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis
    Kivitz, AJ
    Nayiager, S
    Schimansky, T
    Gimona, A
    Thurston, HJ
    Hawkey, C
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (11) : 1189 - 1198
  • [7] Safety and tolerability of rituximab retreatment in patients with active rheumatoid arthritis
    Emery, P
    Fleischmann, RM
    Pavelka, K
    Kaell, AT
    Szechiniski, JZ
    Hooper, MM
    Li, NF
    Garg, JP
    Rowe, KA
    Lehane, PB
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S341 - S341
  • [8] Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
    Emery, Paul
    Rondon, Juan
    Parrino, Janie
    Lin, Yong
    Pena-Rossi, Claudia
    van Hoogstraten, Hubert
    Graham, Neil M. H.
    Liu, Nancy
    Paccaly, Anne
    Wu, Richard
    Spindler, Alberto
    RHEUMATOLOGY, 2019, 58 (05) : 849 - 858
  • [9] Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients
    Hartmann, SN
    Rordorf, CM
    Milosavljev, S
    Branson, JM
    Chales, GH
    Juvin, RR
    Lafforgue, P
    Le Parc, JM
    Tavernier, CG
    Meyer, OC
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (10) : 1582 - 1587
  • [10] SAFETY AND TOLERABILITY OF IGURATIMOD IN RHEUMATOID ARTHRITIS WITH COMORBID ILLNESSES
    Takasugi, K.
    Okada, M.
    Min, C.
    Kitada, A.
    Kataoka, Y.
    Kaneshita, S.
    Suda, M.
    Ohara, Y.
    Rokutanda, R.
    Shimizu, H.
    Tsuda, T.
    Yamaguchi, K.
    Yamaguchi, K.
    Kishimoto, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1039 - 1039
12345